TWI418373B - Platelet adhesion-resistant material - Google Patents

Description

Antiplatelet patch

The invention relates to a novel anti-platelet-attached polyurethane material, which can be applied to the technical field of medical equipment, in particular as a medical catheter main material or a medical catheter surface treatment resin, in order to achieve anti-platelet adhesion effect. .

The blood does not condense or block under normal conditions in the human body. However, when foreign substances such as medical polymer materials invade the human body, the flow state of the blood and the properties of the blood vessel wall are necessarily changed. In addition, if the material itself has an eluate (such as an acid-base substance) entering the blood, it will also change the properties of the blood. These factors are very easy to start blood to form a blood clot and cause blood vessel obstruction. This phenomenon often occurs when treating patients, which will bring great worries to medical care. The more commonly used medical material is polyurethane (PU), which has better biocompatibility than silicone and polyvinyl chloride (PVC), but in anti-platelet attachment. The nature is still not good.

At present, methods for improving the anti-platelet attachment properties of PU mainly include chemical and physical modification methods to modify the properties of the material, thereby achieving the function of anti-platelet attachment.

Regarding the physical improvement method, in 1970, scholar Lyman had discovered that the use of micro-domains of polyurethane-urea (PUU) can reduce the adhesion of platelets (see DJ Lyman, K. Knutson, and B). McNeil, Trans Am Soc Artif Intern Organs., 21:49-53. (1975)). The use of 4,4'-diphenylmethane diisocyanate (MDI) and poly(tetramethylene oxide (PTMO)) is also disclosed in U.S. Patent No. 4,687,831. And PUU synthesized by 4,4'-diaminobenzanilide with microphase separation structure shows less platelet adhesion and has good antithrombotic properties and mechanical properties as an elastomer, so as to be suitable as artificial blood vessels, kidneys and hearts, for example. The material of the organ. It further reveals that this separation structure must have an optimal anti-platelet adhesion effect at 10-20 nm. Although PU has higher biocompatibility than other polymer materials, it still causes platelet adhesion and thrombosis.

Another anti-platelet attachment method is chemical modification. The PU material is surface-modified, and a specific function molecule such as a natural anticoagulant substance, a hydrophilic group and/or an anionic functional group is introduced on the surface of the PU material. To further improve the biocompatibility between materials and blood. Such surface modification methods can be divided into the following types:

(1) Material surface biomimetic

The most common method is to introduce the natural anticoagulant factor Heparin on the surface of polymer materials. The main mechanism is that heparin can form a complex with anithrombin III in blood to inhibit the initiation of clotting factors and achieve anticoagulant effect. Effect (see J. Fareed, Seminars in Thrombosis and Hemostasis, 11(1): 1-9 (1985)). In addition, such as the introduction of albumin (see M. Munro, AJ Quattrone, SR Ellsworth, P. Kulkarni, American Society for Artificial Internal Organs, 27: 499-503 (1981)) or diionic materials such as phosphorylcholine ( Phosphorylcholine, PC) (see K. Ishihara, R. Aragaki, T. Ueda, A. Watenabe and N. Nakabayashi, J. Biomed. Mater. Res. 24, 1069 (1990)), etc., can also improve materials and blood Biocompatible to achieve anti-platelet adhesion.

(2) The surface of the material is hydrophilic

The most common is the introduction of hydrophilic groups such as polyethylene (poly(ehtylene glycol); PEG) and polyethylene oxide (PEO) by plasma or chemical grafting on the surface of common materials. (See D. k. Han, SY Jeong and YH Kim, J. Biomed. Mater. Res. Appl. Biomater. 23(A2), 211. (1989); and KD Park, WG Kim, H. Hacobs, T. Okano and SW Kim, J. Biomed. Mater. Res. 26, 739 (1992)), which focuses on the fact that PEG itself is not toxic and has very good biocompatibility. By introducing hydrophilic PEG or PEO on the surface of the material, a villus-like swing can be formed on the surface of the material to reduce platelet adhesion and achieve an antithrombotic effect.

(3) The surface of the material has a negative charge

The platelets in the blood itself are negatively charged, so there are studies based on the principle of charge homosexual repelling. If the surface of the material increases its anion property, the antiplatelet adhesion effect can be achieved. It is also mentioned in the literature that, in the above method, if an anionic functional group such as a sulfonate is introduced at the end of the hydrophilic group PEG, and the biological activity similar to the natural anticoagulant heparin is exhibited in the blood, it also exhibits good resistance. Platelet adhesion effect (see J. Jozefonvicz and M. Jozefowicz, J. Biomater. Sci. Polymer Edn 1, 147 (1990); DK Han, NY Lee, KD Park, YH Kim, HI Cho and BG Min, Biomaterials 16, 467 (1995) KD Park, WK LEE, JE LEE, YH KIM, ASAIO Journal. 42(5): 876-880 (1996); and DK Han, KD Park, YH Kim, J. of Biomaterials Science-Polymer Edition., 9 ( 2): 163-174. (1998)). The invention is mainly based on the argument that the surface of the material has a negative charge and has an anti-platelet adhesion effect, and further proposes a novel polytriuret-urethane (PTU). Since the PTU material itself comprises a triuret repeating structural unit of the following formula (I), which can improve the material's electrical properties, according to the principle of charge isotropic repelling, the platelets are not easily attached to the surface of the PTU material, thereby eliminating the need for Another graft modification can achieve good anti-platelet adhesion.

It is therefore an object of the present invention to provide an anti-platelet patch comprising polytriuret which is substantially composed of repeating structural units represented by the following formulas (I), (II) and (III), and When the sum of the number of the three repeating structural units in the polytriuret is 100, the proportion of the repeating structural unit (I) is about 5 to 50.

Wherein each R is independently a C ₂ -C ₁₆ alkylene group, a C ₆ -C ₃₀ aromatic group or a C ₆ -C ₃₀ alicyclic group; n is an integer from 2 to 16; and R ₁ Is -(OC _m H _2m ) _p , and m is an integer from 2 to 5, and p is an integer from 3 to 150.

A further object of the present invention is to provide an anti-platelet patch material comprising urea; selected from the group consisting of C ₂ - C ₁₆ aliphatic diisocyanates, C ₆ - C ₃₀ aromatic diisocyanates, C ₆ - C ₃₀ alicyclic groups Diisocyanate, a combination thereof, a diisocyanate; a C ₂ -C ₁₆ diol; and a polytrimethylene ester synthesized from a polyglycol, wherein the urea is used in an equivalent ratio to the diol and the polyglycol It is from about 1:1 to about 1:19.

The anti-platelet patch material of the present invention can be used as a medical catheter main body material or a medical catheter surface treatment resin.

The invention is mainly based on the argument that the surface of the material has a negative charge and has an anti-platelet adhesion effect, and further proposes a polytrimide material (PTU) having a novel structure. Since the PTU material itself has a special formula (I) triuret repeating structural unit to improve the material's anatase, and according to the principle of charge isotropic repelling, the platelet is not easily attached to the surface of the polyuretamine material of the present invention. Has a good anti-platelet adhesion effect.

It is well known that the polyurethane structures generally mentioned are mainly composed of diisocyanates, polyglycols and diols. The main feature of the present invention is that the urea compound is replaced by urea (urea) to replace the partial diol and the polyglycol, so that the synthesized PTU has a negatively charged triuret segment, thereby achieving an anti-platelet adhesion effect. The PTU material of the invention not only has high biocompatibility, but also increases the industrial utilization and the safety of medical equipment. In addition, since the material does not need to be additionally grafted and modified, the manufacturing cost and the application convenience can be reduced.

The PTU of the present invention is substantially composed of repeating structural units represented by the following formulas (I), (II) and (III), and the total number of the three repeating structural units in the polytriuret is 100. , the proportion of the repeating structural unit (I) is about 5 to 50

The PTU of the present invention comprises a triuret repeating structural unit of the formula (I) which allows it to generate a negative charge. Since the N atom in the structure of the formula (I) is bonded to two electron withdrawing groups, the NH bond is easily deprotonated in a neutral or weakly alkaline environment to form a compound of the structure (IV), thereby The inventive PTU material has a negative charge and increases the material's own electrical properties. According to the principle of charge isotropic repulsion, platelets are not easily attached to the surface of the PTU material of the present invention.

In the above chemical formulae (I) to (IV), each R is independently a C ₂ -C ₁₆ alkylene group, a C ₆ -C ₃₀ aromatic group or a C ₆ -C ₃₀ alicyclic group; n is An integer of 2 to 16, preferably an integer of 2 to 10, preferably an integer of 3 to 6; and R ₁ is -(OC _m H _2m ) _p , and m is an integer of 2 to 5, and p is 3~ An integer of 150, preferably an integer from 3 to 100, more preferably an integer from 10 to 50.

According to the present invention, the term "C ₂ -C ₁₆ alkylene" means a straight or branched saturated divalent hydrocarbon molecular group of C ₂ -C ₁₆ , preferably a linear or branched C ₂ -C ₁₂ chain. The saturated divalent hydrocarbon molecular group is more preferably a C ₂ to C ₆ linear or branched saturated divalent hydrocarbon molecular group. Exemplary alkylene groups include, but are not limited to, hexamethylene, 1,6-hexylene, butyl, trimethylhexamethylene, and the like.

According to the present invention, the term "C ₆ -C ₃₀ aromatic group" means a C ₆ -C ₃₀ divalent unsaturated hydrocarbon molecular group having an unsaturated aromatic ring, preferably having an unsaturated aromatic group. bivalent aromatic ring of C ₆ ~ C ₁₅ unsaturated hydrocarbon molecules. Exemplary aromatic groups include, but are not limited to, phenyl, 4,4'-methylenediphenyl, tolyl, anthranyl, and the like.

According to the present invention, the term "C ₆ -C ₃₀ alicyclic group" means a C ₆ -C ₃₀ divalent saturated hydrocarbon molecular group having a saturated carbocyclic ring, preferably a C ₆ having a saturated carbocyclic ring. ~C ₁₅ bivalent saturated hydrocarbon molecular group. Exemplary alicyclic groups include, but are not limited to, cyclohexylene, 4,4'-methylenebicyclohexyl, And similar groups.

The anti-platelet-attached PTU material of the present invention is a polyurethane material synthesized from urea, a polyglycol, a diol and a diisocyanate, and has a molecular weight of 10,000 to 200,000, preferably 30,000 to 150,000, and most preferably 40,000 to 100,000. It is well known in the art to those skilled in the art that the commonly mentioned polyurethane materials are mainly synthesized from diisocyanates, polyglycols and diols, and the main feature of the invention is to replace the moieties by using urea. The diol and the polyglycol are prepared according to a conventional polyurethane synthesis process, so that the synthesized PTU has a negatively charged triuret repeating structural unit of the formula (I) to achieve an anti-platelet adhesion effect. The equivalent ratio of urea to glycol and polyglycol used during the preparation is from about 1:1 to about 1:19, preferably from about 1:1.8 to 1:6.

According to the invention, the diol is a C ₂ -C ₁₆ diol, preferably a C ₂ -C ₁₀ diol. Exemplary diols include, but are not limited to, ethylene glycol (Ethylene Glycol), Propylene Glycol, Butylene Glycol, Pentanediol, Hexanediol, derivatives thereof or Its combination.

Polyglycols which can be used in the present invention include, but are not limited to, Polyethylene Glycol, Poly(propylene glycol), PPG, Poly(ethylene glycol), PTMEG. , a derivative thereof or a combination thereof. According to an embodiment of the present invention, the polyglycol used has a molecular weight of 200 to 9000, preferably has a molecular weight of 200 to 5,000, more preferably has a molecular weight of 200 to 2,000.

Diisocyanates which may be used in accordance with the present invention include C ₂ -C ₁₆ aliphatic diisocyanates, C ₆ -C ₃₀ aromatic diisocyanates, C ₆ -C ₃₀ alicyclic diisocyanates, derivatives thereof, and combinations thereof. Preferred aliphatic diisocyanates include, but are not limited to, hexamethylene diisocyanate (HDI), 1,6-hexylene diisocyanate, tetramethylene diisocyanate, trimethylhexamethylene diisocyanate Or a derivative thereof. Preferred aromatic diisocyanates include, but are not limited to, diphenylmethane-4,4'-diisocyanate (MDI), toluenediisocyanate (TDI), 1,5-naphthalene. 1,5-naphthalene diisocyanate (NDI), p-phenylene diisocyanate (PPDI) or a derivative thereof. Preferred alicyclic diisocyanates include, but are not limited to, cyclohexane diisocyanate, isophorone diisocyanate (IPDI), dicyclohexylmethane diisocyanate (H ₁₂ MDI) or derivatives thereof. .

The following examples are intended to illustrate the invention, but are not intended to limit the scope of the invention. Modifications and variations that may be readily made by those skilled in the art are within the scope of the disclosure of the present disclosure and the scope of the appended claims.

Example Synthetic chemicals

Diphenylmethane 4,4'-diisocyanate (MDI, 98%), hydrogenated diphenylmethane diisocyanate (H ₁₂ MDI, 90%), isophorone diisocyanate (IPDI, 98%), polyethylene glycol (PEG; Avg. Mn~2000), 1,4-butanediol (1,4-Butanediol, BD, 99%), urea (urea, 99.0-100.5%), and polyethyleneimine (PEI) It was purchased from Sigma; Eastman 58245 was purchased from Noveon; Dimethyl acetamide (DMAC, reagent grade) was purchased from TEDIA, and fresh DMAC was obtained by distillation before the reaction, and then the reaction was carried out.

PTU synthesis preparation Preparation Example 1: Synthesis of PTU with Urea 15% (PTU1)

Take 1 equivalent of polyethylene glycol in a 500 mL four-neck reaction flask, place it in a vacuum oven before heating and heat to 100 ° C, remove water for 8 hours under a vacuum of 1 torr, add 30 mL of fresh DMAC, again at 60 ° C. The degree of vacuum was 1 Torr and water was removed for 2 hours. Add 2.4 equivalents of 1,4-butanediol, and raise the temperature to 80 ° C, about half an hour to reach temperature equilibrium, then add 0.6 equivalents of urea, then add 4 equivalents of MDI for polymerization, MDI must be added in portions, each The amount of addition is 0.02 to 0.05 equivalents. In addition, when the MDI is added, the viscosity will rise. At this time, DMC dilution must be added to prevent the gel from being generated. Repeat the cycle of adding MDI, increasing the viscosity of the polymer to be diluted, and the viscosity of the polymer is not After raising again, methanol was added to quench the reaction, and the product was precipitated in ice water.

Preparation Example 2: Synthesis of PTU with Urea 25% (PTU2)

Take 1 equivalent of polyethylene glycol in a 500 mL four-neck reaction flask, place it in a vacuum oven before heating and heat to 100 ° C, remove water for 8 hours under a vacuum of 1 torr, add 30 mL of fresh DMAC, again at 60 ° C. The degree of vacuum was 1 Torr and water was removed for 2 hours. Add 2 equivalents of 1,4-butanediol, and raise the temperature to 80 ° C, about half an hour to reach temperature equilibrium, then add 1 equivalent of urea, then add 4 equivalents of MDI for polymerization, MDI must be added in portions, each The amount of addition is 0.02 to 0.05 equivalents. In addition, when the MDI is added, the viscosity will rise. At this time, DMC dilution must be added to prevent the gel from being generated. Repeat the cycle of adding MDI, increasing the viscosity of the polymer to be diluted, and the viscosity of the polymer is not After raising again, methanol was added to quench the reaction, and the product was precipitated in ice water.

Preparation Example 3: Synthesis of PTU with Urea 35% (PTU3)

Take 1 equivalent of polyethylene glycol in a 500 mL four-neck reaction flask, place it in a vacuum oven before heating and heat to 100 ° C, remove water for 8 hours under a vacuum of 1 torr, add 30 mL of fresh DMAC, again at 60 ° C. The degree of vacuum was 1 Torr and water was removed for 2 hours. Add 1.25 equivalents of 1,4-butanediol, raise the temperature to 80 ° C, reach the temperature equilibrium for about half an hour, add 1.25 equivalents of urea, and then add 3.5 equivalents of MDI to carry out the polymerization. MDI must be added in several portions. The amount of addition is 0.02 to 0.05 equivalents. In addition, when the MDI is added, the viscosity will rise. At this time, DMC dilution must be added to prevent the gel from being generated. Repeat the cycle of adding MDI, increasing the viscosity of the polymer to be diluted, and the viscosity of the polymer is not After raising again, methanol was added to quench the reaction, and the product was precipitated in ice water.

Preparation Example 4: Synthesis of PTU with Urea 35% (PTU4)

Take 1 equivalent of polyethylene glycol in a 500 mL four-neck reaction flask, place it in a vacuum oven before heating and heat to 100 ° C, remove water for 8 hours under a vacuum of 1 torr, add 30 mL of fresh DMAC, again at 60 ° C. The degree of vacuum was 1 Torr and water was removed for 2 hours. Add 1.25 equivalents of 1,4-butanediol, raise the temperature to 80 ° C, reach the temperature equilibrium for about half an hour, add 1.25 equivalents of urea, and then add 3.5 equivalents of H ₁₂ MDI for polymerization. MDI must be added in several portions. , the amount of each addition is 0.02 ~ 0.05 equivalents. In addition, when the MDI is added, the viscosity will rise. At this time, DMC dilution must be added to prevent the gel from being generated. Repeat the cycle of adding MDI, increasing the viscosity of the polymer to be diluted, and the viscosity of the polymer is not After raising again, methanol was added to quench the reaction, and the product was precipitated in ice water.

Preparation Example 5: Synthesis of PTU with Urea 35% (PTU5)

Take 1 equivalent of polyethylene glycol in a 500 mL four-neck reaction flask, place it in a vacuum oven before heating and heat to 100 ° C, remove water for 8 hours under a vacuum of 1 torr, add 30 mL of fresh DMAC, again at 60 ° C. The degree of vacuum was 1 Torr and water was removed for 2 hours. Add 1.25 equivalents of 1,4-butanediol, raise the temperature to 80 ° C, reach the temperature equilibrium for about half an hour, add 1.25 equivalents of urea, then add 3.5 equivalents of IPDI to carry out the polymerization, MDI must be added in portions, each The amount of addition is 0.02 to 0.05 equivalents. In addition, when the MDI is added, the viscosity will rise. At this time, DMC dilution must be added to prevent the gel from being generated. Repeat the cycle of adding MDI, increasing the viscosity of the polymer to be diluted, and the viscosity of the polymer is not After raising again, methanol was added to quench the reaction, and the product was precipitated in ice water.

Comparative Example 1: PU1

As a sample of this preparation example, it was dissolved in DMAC (about 20% by weight) by heating at 80 ° C using Eastman 58245 sold by Noveon.

Comparative Example 2: PU2

The PU synthesis technique is carried out according to the PU synthesis technique disclosed in U.S. Patent No. 4,687,831, and the synthesis of the present invention is carried out in accordance with the synthesis technique disclosed in this patent.

Comparative Example 3: PEI

A polyethyleneimine (PEI) sold by Sigma was used as a sample of this preparation example.

Sample film formation PTU film formation method:

The polytriuret obtained by the synthesis of Preparation Examples 1 to 5 was dissolved in DMAC (about 20% by weight) by heating, and the polymer-containing DMAC solvent was coated to form a film, which was set. The DMAC solvent was removed in an oven at 90 ° C for 2 hours to obtain a dried PTU film.

PU film formation method:

The polyurethane materials of Comparative Examples 1 to 2 were heated and dissolved in DMAC (about 20% by weight), and the polymer-containing DMAC solvent was coated into a film, which was placed in an oven at 90 ° C. 2 The DMAC solvent was removed to obtain a dried PU film.

PEI film formation method:

The sample of Comparative Example 3 was coated on a film, which was placed in an oven at 90 ° C for 2 hours to obtain a dried PEI film.

Surface potential measurement

The PTU film was lyophilized and pulverized into a powder, and the surface potential was examined using the powder to confirm the surface electrical properties of the PTU and to observe changes in surface electrical properties depending on the urea content.

Experimental results:

It can be observed from Table 1 that the polytriuret (PTU) synthesized by Urea of the present invention has a higher anion property than the commercially available polyurethane material, and the higher the urea content, the higher the PTU. The stronger the electrical property, the higher the negative electrical property, the more negative charge it carries, and the negative charge in the platelets will form a negative charge. This situation can reduce the ratio of platelet adhesion and thus achieve antiplatelet. Attached features.

Platelet adhesion test Preparation Examples 1 to 5:

Experimental step 1:

The fresh pig blood plasma was separated by a centrifuge (1500 rpm; 15 min) to obtain PPP (Plasma Poor Platelet) having a platelet content of 17 × 10 ³ to 20 × 10 ³ / μl.

Experimental step 2:

The film-formed PTU material was cut into an area of 1 cm ² and rinsed with PBS buffer, and the PTU was fixed on a glass plate.

Experimental step 3:

1 ml of fresh PPP was applied to the surface of PTU, and PPP was aspirated after standing at room temperature for 2 hours. The number of PPP residual platelets was counted by a hemocytometer, and the platelet adsorption condition of the material was calculated by the following formula.

Comparative Examples 1 to 3

The PU and PEI films were tested for platelet attachment in the same manner as in Experimental Procedures 2 and 3 of Preparation Examples 1 to 5, as experimental control groups.

Platelet adhesion test results:

In the platelet attachment experiment, the PEI material which is easy to make the platelet attached and the commonly used PU as the experimental control material of the present invention are used as the experimental control results. It can be clearly seen from Fig. 1 that the PTU has more negative charge on the surface, and has better anti-platelet adhesion effect than the general PU and PEI with positive charge on the surface, and PTU anti-platelet can also be seen. The effect of the attachment will increase with the urea content, so that the stronger the positive electrical property of the PTU, the stronger the negative electrical property means the more negative charge, and the negative charge in the platelet will form a negative charge. Reduce the rate of platelet adhesion, which in turn makes the anti-platelet adhesion effect better. Therefore, the lower the adsorption rate of platelets, the better the function of anti-platelet attachment.

It should be readily understood that various modifications of the invention are possible and are readily recognized and contemplated by those skilled in the art.

Figure 1 shows the results of platelet attachment experiments.

(no component symbol description)

Claims (20)

An anti-platelet patch material comprising polytriuret which is substantially composed of repeating structural units represented by the following formulas (I), (II) and (III), and the polyuretamine ester When the sum of the number of the three repeating structural units is 100, the proportion of the repeating structural unit (I) is about 5 to 50. Wherein each R is independently a C ₂ -C ₁₆ alkylene group, a C ₆ -C ₃₀ aromatic group or a C ₆ -C ₃₀ alicyclic group; n is an integer from 2 to 16; and R ₁ Is -(OC _m H _2m ) _p , and m is an integer from 2 to 5, and p is an integer from 3 to 150. The anti-platelet patch material of claim 1, wherein each R is independently a C ₂ -C ₁₂ alkyl group, a C ₆ -C ₁₅ aromatic group or a C ₆ -C ₁₅ alicyclic group; An integer from 2 to 10; and p is an integer from 3 to 100. The anti-platelet patch material of claim 1, wherein each R is independently a C ₂ -C ₆ alkylene group, a C ₆ -C ₁₅ aromatic group or a C ₆ -C ₁₅ alicyclic group; An integer from 3 to 6; p is an integer from 10 to 50. The anti-platelet patch material of claim 1, wherein each R is independently hexamethylene, 1,6-hexylene, butyl, trimethylhexamethylene, phenyl, 4,4'- Methylene diphenyl, tolyl, anthranyl, cyclohexyl, 4,4'-methylenebicyclohexyl or . The anti-platelet patch material according to any one of claims 1 to 4, wherein the polytriuret-containing ester has a molecular weight of 10,000 to 200,000. The anti-platelet patch material of claim 5, wherein the polytriuret-containing ester has a molecular weight of 30,000 to 150,000. The anti-platelet patch material of claim 6, wherein the polytriuret-containing ester has a molecular weight of 40,000 to 100,000. The anti-platelet patch material according to any one of claims 1 to 4, which is used as a medical catheter main body material or a medical catheter surface treatment resin. An anti-platelet patch material comprising urea; selected from the group consisting of C ₂ - C ₁₆ aliphatic diisocyanates, C ₆ - C ₃₀ aromatic diisocyanates, C ₆ - C ₃₀ alicyclic diisocyanates, and combinations thereof Isocyanate; a C ₂ -C ₁₆ diol; and a polytriamine compound synthesized from a polyglycol, wherein the urea and the diol and the polyglycol are used in an equivalent ratio of from about 1:1 to about 1. :19. The anti-platelet patch material of claim 9, wherein the C ₂ -C ₁₆ aliphatic diisocyanate is Hexamethylene diisocyanate (HDI), 1,6-hexylene diisocyanate, tetramethylene di Isocyanate, trimethylhexamethylene diisocyanate or a derivative thereof. The antiplatelet patch of claim 9, wherein the C ₆ - C ₃₀ aromatic diisocyanate diphenylmethane-4, 4'-diisocyanate (MDI), toluene diisocyanate (diphenylmethane-4, 4'-diisocyanate; MDI) Toluenediisocyanate, TDI), 1,5-naphthyl diisocyanate (1,5-NAPHTHALENE DIISOCYANATE; NDI), p-phenylene diisocyanate (PPDI) or a derivative thereof. The antiplatelet patch of claim 9, wherein the C ₆ - C ₃₀ cycloaliphatic diisocyanate cyclohexane diisocyanate, isophorone diisocyanate (IPDI), hydrogenated diphenylmethane diisocyanate (dicyclohexylmethane) Diisocyanate; H ₁₂ MDI) or a derivative thereof. The anti-platelet patch material of claim 9, wherein the C ₂ -C ₁₆ diol is ethylene glycol (Ethylene Glycol), propylene glycol (Propylene Glycol), butylene glycol (Butylene Glycol), and pentanediol (Pentanediol). , Hexanediol, derivatives thereof or combinations thereof. The anti-platelet patch material of claim 9, wherein the polyglycol is polyethylene glycol (polyethylene glycol), polypropylene (poly(propylene glycol); PPG), poly(tetramethylene glycol) ; PTMEG), its derivatives or a combination thereof. The anti-platelet patch material of claim 14, wherein the polyglycol has a molecular weight of from 200 to 9000. The anti-platelet patch material of claim 15, wherein the polyglycol has a molecular weight of 200 to 5000. The anti-platelet patch material of claim 16, wherein the polyglycol has a molecular weight of from 200 to 2,000. The anti-platelet patch material according to any one of claims 9 to 17, wherein the polytriuret-containing ester has a molecular weight of 40,000 to 100,000. The anti-platelet patch material of any one of claims 9 to 17, wherein the use ratio of the urea to the diol and the polyglycol is from about 1:1.8 to about 1:6. The anti-platelet patch material according to any one of claims 9 to 17, which is used as a medical catheter main body material or a medical catheter surface treatment resin.